Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Alan Colowick MD Is Appointed to the BOD of Harpoon Therapeutics

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Alan Colowick, MD is an experienced biotech leader and has served in numerous executive and board roles.

“We are thrilled to welcome Dr. Colowick as the newest member of the Harpoon Board of Directors,” said Ron Hunt, Chairman of the Board of Directors of Harpoon Therapeutics. “Alan is an accomplished industry leader who has managed and served on the boards of numerous innovative life science companies and he brings extensive experience and knowledge at this pivotal period of growth for Harpoon.”

“I am delighted to join Harpoon’s Board of Directors during this important period of clinical development activity for the company,” stated Alan Colowick, M.D. “Harpoon has made tremendous progress in a short time evolving into a clinical-stage organization with an exciting pipeline of potential immune-oncology therapies that could make a meaningful difference in the lives of patients with cancer.”

Throughout his career, Dr. Colowick has had a broad impact across the healthcare landscape with a focus on clinical-stage companies in oncology, rare diseases and other specialty therapeutic areas.

From May 2017 until January 2021, he served as a partner and executive partner with Sofinnova Ventures and led investments in Velos Biopharma, Xylocor, and InCarda. He also served as Chair of Principia Biopharma from April 2019 until its acquisition by Sanofi in September 2020, and as its Executive Chair from February 2017 to April 2019.

Prior to Sofinnova, he was with Celgene Corporation from 2010 to 2017 serving most recently as Executive Vice President where he focused on strategic and growth opportunities and an operational plan to leverage Big Data across the corporation.

From 2008 until its acquisition by Celgene in 2010, he was CEO of Gloucester Pharmaceuticals. Prior to Gloucester Pharmaceuticals, he was President, Oncology at Geron Corporation, and was Chief Medical Officer at Threshold Pharmaceuticals. Dr. Colowick holds an M.D. from Stanford University School of Medicine, an M.P.H. from Harvard School of Public Health, and a B.S. in Molecular Biology from the University of Colorado.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine